Generic Medicine Info
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Hypersensitivity to cefadroxil or other cephalosporins.
Special Precautions
Patient with history of hypersensitivity to penicillins or any other β-lactam drugs, severe allergy or asthma; history of gastrointestinal disease, especially colitis. Renal impairment. Pregnancy and lactation. Monitoring Parameters Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Monitor renal function test, LFTs and blood count frequently on long-term use; signs and symptoms of anaphylaxis during 1st dose.
Adverse Reactions
Significant: Hypersensitivity reactions, including anaphylaxis; Clostridium difficile-associated diarrhoea. Blood and lymphatic system disorders: Rarely, eosinophilia, neutropenia, thrombocytopenia, agranulocytosis. Gastrointestinal disorders: Diarrhoea, nausea, vomiting, dyspepsia, abdominal pain, glossitis. General disorders and administration site conditions: Rarely, fever. Immune system disorders: Rarely, serum sickness-like reaction, angioneurotic oedema. Investigations: Rarely, slightly elevated AST and ALT. Musculoskeletal and connective tissue disorders: Rarely, arthralgia. Skin and subcutaneous tissue disorders: Rash, pruritus, allergic exanthema, urticaria.
Potentially Fatal: Pseudomembranous colitis.
Drug Interactions
May cause an antagonistic effect with bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol). May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May cause haemorrhagic complications with prolonged use of anticoagulant or thrombocyte inhibitors. May increase plasma concentration with probenecid. May decrease bioavailability with colestyramine.
CIMS Class
ATC Classification
J01DB05 - cefadroxil ; Belongs to the class of first-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on cefadroxil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in